


## (Rac)-JBJ-04-125-02 acetate

<b>Cat. No.:</b>	HY-135805B
<b>Molecular Formula:</b>	C <sub>29</sub> H <sub>26</sub> FN <sub>5</sub> O <sub>3</sub> S.1/3C <sub>2</sub> H <sub>4</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	563.63
<b>Target:</b>	EGFR
<b>Pathway:</b>	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 115 mg/mL (204.03 mM; Need ultrasonic)					
	<b>Preparing Stock Solutions</b>	<b>Solvent Concentration</b>	<b>Mass</b>	<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		<b>1 mM</b>		1.7742 mL	8.8711 mL	17.7421 mL
		<b>5 mM</b>		0.3548 mL	1.7742 mL	3.5484 mL
		<b>10 mM</b>		0.1774 mL	0.8871 mL	1.7742 mL
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.87 mg/mL (5.09 mM); Clear solution					

### BIOLOGICAL ACTIVITY

<b>Description</b>	(Rac)-JBJ-04-125-02 acetate is the racemate of JBJ-04-125-02. JBJ-04-125-02 is a potent, selective mutagenesis, allosteric and orally active EGFR inhibitor <sup>[1]</sup> .
--------------------	--

### REFERENCES

[1]. To C, et al. Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. Cancer Discov. 2019 Jul;9(7):926-943.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA